STOCKHOLM, Jan. 14, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly...
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US )
Also on site :
- Bodies of two Israeli-American hostages recovered from Gaza in joint military operation
- Second interview with AUC professor Bahgat Korany discusses Suez Canal, GERD concerns & global politics
- Philadelphia Cream Cheese Shakes Up Classic Recipe With Limited-Edition Offer